Can QRx Pharma Land A Positive FDA Decision?
(Thomson Reuters ONE) -
Sydney, Australia based QRx Pharma (PINK:QRXPY) (PINK:QRXPF) (ASX:QRX) is a
pharmaceutical company with the vast majority of its prospects tied up in a
single drug - MoxDuo. MoxDuo is a combination of two widely used opioids (3:2
ratio of morphine and oxycodone).
In the combination of these two into a single analgesic, QRx claims that
synergetic effects are possible which can ultimately reduce dosage and side-
effects for patients undergoing pain therapy.
Since the market for pain medications is enormous, at about $2.5 billion, QRx
hopes to demonstrate that their patented MoxDuo formula can outperform the
originals and carve out a sizable piece of that market share. To better cater to
the drug market, their protected formula is being developed in three forms -
immediate release, controlled release, and intravenous. In addition, the Swiss
pharmaceutical company Actavis has signed a License and Option Agreement (LOA)
to help commercialize MoxDuo IR.
MoxDuo immediate release capsules will be the first commercially available
product if all goes well. After almost four years of phase III trials and an NDA
submission on August 25(th) 2011, the drug sits somewhere in a large stack of
FDA paperwork as an NDA with a PDUFA action date of June 25(th) listed on the
BioMedReports FDA Calendar.
Although there are technically three compounds undergoing clinical trials, the
real test for QRx is in the approaching FDA decision. An approval of MoxDuo IR
will pave a much easier path for the intravenous and controlled-release versions
of the drug, since the active ingredients identical. The decision rests heavily
on the lone phase III dose-response study in acute pain. The study, which
involved 256 patients, tested four dosages of MoxDuo using the numeric pain
rating scale (NPRS), with the primary endpoint being the summation of pain
intensity differences over 48 hours relative to the baseline.
The results were statistically significant and clear from the data, but NDA
decisions aren't that clearly predicted. We could see a rejection of the current
data due to a lack of comparison to previous approved pain medication
alternatives, or some other issue that wasn't explored to its fullest potential.
Since QRx is highly dependent on MoxDuo, We expect that the FDA decision
regarding MoxDuo IR will have tremendous impact on the price of shares. A clean
approval could cause shares to continue another leg in their multi-year rally,
perhaps going as high as $3/share. On the other hand, a rejection could bring up
fears over the true efficacy of the morphine/oxycodone combination and spark a
major selloff which could send shares into a ditch for a while. So, for the most
part, QRXPY is simply a high-stakes gamble in the FDA's decision on June 25(th).
The full report on QRx Pharma from Brian Wilson is available at:
http://www.biomedreports.com/2012062097745/qrx-pharma-a-high-stakes-gamble-in-
the-fdas-upcoming-decision.html
Healthcare investors and Biotech traders interested in accessing BioMedReports'
new complete database of clinical trials and upcoming FDA and world-wide
regulatory decisions which can be used to make more profitable trades and see
upcoming catalysts can go to:
http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly
via twitter at: http://twitter.com/BioMedReports
####
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news
and the entire Healthcare Sector of the market. BioMedReports is not paid or
compensated to report the news and developments of publicly traded companies.
BioMedReports sells a premium product for subscribers and full disclosures and
information about the stocks and news mentioned in this news release is
available at BioMedReports.Com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioMedReports via Thomson Reuters ONE
[HUG#1620891]
Datum: 20.06.2012 - 13:02 Uhr
Sprache: Deutsch
News-ID 158348
Anzahl Zeichen: 4808
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 223 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Can QRx Pharma Land A Positive FDA Decision?"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
